Redeye updates its estimates following Carasent’s Q2’22 report, which was a tad weaker than anticipated. Both the organic growth and margins came in below estimates. On the bright side, the customer intake was very strong, and Carasent also signed its first Webdoc NO customer.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/